Eliana Merle
Stock Analyst at Barclays
(3.37)
# 944
Out of 5,174 analysts
108
Total ratings
40.96%
Success rate
5.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Maintains: Equal-Weight | $31 → $25 | $15.57 | +60.57% | 6 | Mar 23, 2026 | |
| REGN Regeneron Pharmaceuticals | Initiates: Overweight | $923 | $736.05 | +25.40% | 1 | Mar 6, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $80 → $105 | $54.09 | +94.12% | 4 | Mar 4, 2026 | |
| TPG TPG Inc. | Maintains: Overweight | $69 → $56 | $39.23 | +42.75% | 2 | Mar 2, 2026 | |
| GOSS Gossamer Bio | Downgrades: Underweight | $9 → $0.3 | $0.38 | -20.68% | 5 | Feb 24, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $606 → $607 | $448.73 | +35.27% | 2 | Feb 17, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $59 | $36.01 | +63.84% | 2 | Jan 28, 2026 | |
| SGMT Sagimet Biosciences | Initiates: Equal-Weight | $8 | $4.78 | +67.36% | 2 | Jan 28, 2026 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $68 → $119 | $64.64 | +84.10% | 1 | Jan 28, 2026 | |
| MBX MBX Biosciences | Initiates: Overweight | $66 | $27.71 | +138.18% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $964 | $443.44 | +117.39% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $6.01 | +199.50% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $231 | $141.42 | +63.34% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $342 | $217.89 | +56.96% | 3 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $9.08 | +263.44% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $68.39 | +16.98% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $24 | $17.28 | +38.89% | 9 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $302.59 | +74.16% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $40 → $34 | $52.20 | -34.87% | 9 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $3.37 | +612.17% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $62.88 | -68.19% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $17.85 | -32.77% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $1.87 | +327.81% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $10.10 | +107.92% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $75.04 | -6.72% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $2.44 | -9.84% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $96.76 | -26.62% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $87.30 | +50.06% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $21.62 | -76.87% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $48.82 | -63.13% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $14.87 | +47.95% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $7.85 | +498.73% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $14.41 | +11.07% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $30.30 | +342.24% | 3 | Aug 19, 2020 |
uniQure
Mar 23, 2026
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $15.57
Upside: +60.57%
Regeneron Pharmaceuticals
Mar 6, 2026
Initiates: Overweight
Price Target: $923
Current: $736.05
Upside: +25.40%
BioMarin Pharmaceutical
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $54.09
Upside: +94.12%
TPG Inc.
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $39.23
Upside: +42.75%
Gossamer Bio
Feb 24, 2026
Downgrades: Underweight
Price Target: $9 → $0.3
Current: $0.38
Upside: -20.68%
Vertex Pharmaceuticals
Feb 17, 2026
Maintains: Overweight
Price Target: $606 → $607
Current: $448.73
Upside: +35.27%
Tyra Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $36.01
Upside: +63.84%
Sagimet Biosciences
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $4.78
Upside: +67.36%
PTC Therapeutics
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $64.64
Upside: +84.10%
MBX Biosciences
Jan 28, 2026
Initiates: Overweight
Price Target: $66
Current: $27.71
Upside: +138.18%
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $443.44
Upside: +117.39%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $6.01
Upside: +199.50%
Jan 28, 2026
Initiates: Overweight
Price Target: $231
Current: $141.42
Upside: +63.34%
Jan 28, 2026
Initiates: Overweight
Price Target: $342
Current: $217.89
Upside: +56.96%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $9.08
Upside: +263.44%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $68.39
Upside: +16.98%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $24
Current: $17.28
Upside: +38.89%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $302.59
Upside: +74.16%
Jan 7, 2026
Assumes: Neutral
Price Target: $40 → $34
Current: $52.20
Upside: -34.87%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $3.37
Upside: +612.17%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $62.88
Upside: -68.19%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $17.85
Upside: -32.77%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $1.87
Upside: +327.81%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $10.10
Upside: +107.92%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $75.04
Upside: -6.72%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.44
Upside: -9.84%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $96.76
Upside: -26.62%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $87.30
Upside: +50.06%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $21.62
Upside: -76.87%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $48.82
Upside: -63.13%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $14.87
Upside: +47.95%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $7.85
Upside: +498.73%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $14.41
Upside: +11.07%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $30.30
Upside: +342.24%